Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Undifferentiated connective-tissue disease

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
New organ-threatening autoimmune disease

Proteinuric AKI, pulmonary haemorrhage, rapidly progressive ILD, myocarditis, severe cytopenia, focal neurological disease, vasculitic neuropathy or thrombosis means the previous undifferentiated label is no longer sufficient.

Action: Admit or assess urgently, stabilise the organ, obtain targeted serology, imaging, fluid or tissue and infection studies, and involve rheumatology with the relevant organ specialty before empirical treatment obscures diagnosis.

Synopsis

Use undifferentiated connective-tissue disease as a precise longitudinal diagnosis when autoimmune features are real but criteria remain incomplete, avoid treating incidental antibodies, monitor organ and pregnancy risk, and reclassify promptly when evidence evolves.

  • UCTD describes persistent clinical autoimmune features with supportive serology that do not meet a defined connective-tissue diagnosis after mimics are assessed; it is not a synonym for positive ANA.
  • Document objective features precisely: Raynaud pattern, swollen joints, ulcers, photosensitive rash, salivary or ocular measures, capillaries, strength, blood counts, urine and organ physiology.
  • ANA titre and pattern alter pre-test interpretation but do not measure activity; anti-Ro, anti-La, RNP, dsDNA, centromere, topoisomerase, myositis and antiphospholipid tests are chosen by phenotype.
  • At baseline check FBC, renal and liver profile, ESR or CRP, urinalysis and quantitative protein when abnormal; add complement, CK, PFT, capillaroscopy or imaging only when the clinical pattern supports them.
  • Most stable mild disease is managed with education, UV and vascular protection, exercise and symptom-targeted treatment rather than broad immunosuppression.
  • Hydroxychloroquine can be considered for persistent inflammatory skin or joint manifestations, with weight-based dosing and retinal monitoring; evidence for preventing progression is uncertain.
  • Do not prescribe long-term glucocorticoid for fatigue, widespread pain or an antibody result; treat objective inflammatory disease and set a stop or taper point.
  • Review more frequently during the first years, with new symptoms or changing serology, because evolution is most likely near onset; stable low-risk disease can use wider intervals.
  • Reclassify when new evidence fits a defined disease and immediately redirect organ screening and treatment; retaining an old UCTD label should never block greater diagnostic precision.
  • Before pregnancy assess disease activity, urine, pressure, anti-Ro, anti-La and antiphospholipid antibodies and change incompatible medicines while stable.

Key red flags

New proteinuria, glomerular haematuria, hypertension or creatinine rise requires urgent renal assessment for lupus, vasculitis, TMA or another kidney disease.

Hypoxia, haemoptysis, falling haemoglobin, rapidly progressive cough or ground-glass change requires emergency respiratory evaluation.

Progressive proximal weakness, dysphagia, weak cough or CK rise requires inflammatory-myopathy and respiratory assessment.

Digital ulcer, progressive skin tightening, severe hypertension or isolated DLCO decline can mark evolution toward systemic sclerosis and PAH risk.

Pregnancy with anti-Ro, anti-La or antiphospholipid antibodies requires specialist planning even when the maternal disease label remains undifferentiated.

Evolution toward lupus

New nephritic urine, anti-dsDNA, low complement, immune cytopenia or characteristic rash should trigger immediate SLE and nephritis reassessment.

Evolution toward myositis

Objective proximal weakness, characteristic rash, dysphagia, CK change or ILD with myositis antibodies requires a dedicated inflammatory-myopathy pathway.

Investigation priorities

01
Structured history and examinationFirst step

Establish whether symptoms represent objective systemic autoimmunity and create a reproducible baseline.

Management branches

First-line formulationProve autoimmunity without overcalling

Persistent systemic symptoms and an ANA result raise concern but no defined CTD is established.

  1. Document objective inflammatory, vascular, glandular, skin and organ findings and review infections, medicines, thyroid disease, malignancy and non-inflammatory pain or fatigue.
  2. Obtain baseline blood, renal and urine tests and phenotype-directed antibodies rather than a blanket panel; use capillaroscopy, PFT, imaging or biopsy only for a specific question.
  3. Record whether UCTD is supported, what organ disease is absent and which new features require urgent review or reclassification.
Preferred mild managementTreat manifestations, not the label

Stable UCTD causes skin, joint, sicca or Raynaud symptoms without major-organ disease.

  1. Use UV protection, warming, smoking cessation, exercise, sleep and local skin, eye, mouth or vascular measures matched to the symptom.
  2. Use a brief NSAID when safe or hydroxychloroquine for persistent objective inflammatory skin or joints, defining benefit and toxicity monitoring before treatment.
  3. Assess fatigue and widespread pain for anaemia, thyroid, sleep, menopause, mood and fibromyalgia and provide non-immunosuppressive rehabilitation.

Key medicines

HydroxychloroquineFor persistent inflammatory skin or joint manifestations use 200–400 mg orally once daily, not exceeding 5 mg/kg actual body weight/day, and continue only when an agreed clinical benefit is demonstrated.Review renal impairment, maculopathy, QT interactions, hypoglycaemia and cardiomyopathy and arrange retinal monitoring after five years or after one year when high risk. BSR considers it compatible with pregnancy and breastfeeding.
Nifedipine modified releaseFor troublesome Raynaud phenomenon start 30 mg orally once daily and increase, commonly to 60 mg once daily, according to response, blood pressure and product.Monitor headache, flushing, oedema, tachycardia, reflux and symptomatic hypotension; ulcers, rest pain or tissue threat requires urgent systemic-sclerosis and vascular assessment.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSR 2026 systemic lupus guidelineUK principles for ANA interpretation, organ screening and lupus-like treatment.
  • BSR 2024 systemic sclerosis guidelineUK Raynaud, capillary, lung and evolving scleroderma risk assessment.
  • BSR Sjogren disease guidelineObjective sicca testing and anti-Ro-associated systemic and pregnancy considerations.
  • British Society for Rheumatology guideline hubOfficial UK access to phenotype-specific CTD guidance; no dedicated UCTD regimen exists.
  • BSR pregnancy prescribing guidelineMedicine compatibility and fetal antibody considerations around pregnancy.
  • Hydroxychloroquine UK product informationLicensed dose, contraindications, interactions and retinal and cardiac safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting review
JurisdictionUnited Kingdom